Novo Nordisk: the company that built the obesity era — now fighting to keep its lead
An independent, fully-cited, deliberately neutral teardown of Novo Nordisk A/S — how a 1923 Danish insulin maker turned a single peptide into the GLP-1 boom, why it lost the lead to Eli Lilly and half its market value, and the pricing, patent, pipeline and governance questions that decide its next decade.
Novo Nordisk spent a century mastering one thing — making peptides like insulin at scale — and then discovered that the same molecule that controls blood sugar also melts away body weight. That insight, sold as Ozempic and Wegovy, briefly made a Danish company headquartered in a Copenhagen suburb the most valuable listed business in Europe. By 2026 the story had inverted: a faster rival, a disappointing trial, a pricing reckoning and a boardroom coup.
In fiscal 2025 Novo grew sales 10% at constant currencies to DKK 309bn and earned net profit of DKK 102bn[13][15] — yet its shares are down roughly 50% from their 2024 peak, its market value has fallen to about $186bnversus Eli Lilly's ~$950bn[54][55], and Lilly now holds around 60% of the GLP-1 market Novo created[20]. The question is no longer whether Novo is profitable — it plainly is — but whether it can re-accelerate against a stronger competitor while prices and patents turn against it. This site lays out both cases and leaves the verdict to you.
Five years of sales: a boom that is still growing, but no longer racing
Novo nearly tripled sales between 2020 and 2025 as Ozempic and Wegovy scaled[13]. But the slope is flattening: growth slowed from the GLP-1 surge to +10% at constant currencies in 2025, and the company guides 2026 adjusted sales to fall 4%–12% as US pricing resets and Lilly takes share[57]. The trajectory below is the central picture: a still-large, highly profitable franchise decelerating, not collapsing.
2025 is reported in the annual report[13]; earlier years are approximate reported totals shown for trajectory. See Financials for detail and the stock story.
The three questions this case study turns on
Can Novo defend the obesity market it created against Eli Lilly?
Novo invented the GLP-1 obesity category with Ozempic and Wegovy, but by 2026 Eli Lilly's tirzepatide and new oral pill control roughly 60% of the GLP-1 market and Lilly is worth about five times more. Bulls point to Wegovy's efficacy edge and a ~65% share of new US category scripts; bears see a structural handover of leadership.
Does the next-generation pipeline restore the lead — or just defend?
The oral Wegovy pill launched strongly and lifted 2026 guidance, and amycretin and CagriSema are in late-stage trials. But CagriSema's headline 22.7% weight loss undershot the ~25% the market wanted, and a semaglutide Alzheimer's trial failed. The pipeline is deep; whether it out-innovates Lilly is unresolved.
How damaging are the pricing reset and the semaglutide patent cliff?
A November 2025 US deal cuts obesity-drug prices toward $245/month, semaglutide patents are already lapsing in markets like Canada, India and China (US protection runs to ~2032), and ~1M Americans used cheaper compounded copies. Novo is still hugely profitable, but the price-and-patent math is tightening fast.
The balance of evidence, at a glance
Why the bull case holds
- Elite economics: ~DKK 128bn operating profit on DKK 309bn sales (~41% margin), DKK 102bn net profit, ~81% gross margin[15][51].
- Wegovy keeps an efficacy edge (~14% vs ~11% weight loss for Lilly's pill) and ~65% of new US category scripts[23].
- A deep next-gen pipeline — oral Wegovy, amycretin, CagriSema — plus SELECT's 20% cardiovascular-event reduction[4][30].
- Patient capital: a foundation that must stay in control and is not forced to sell, funding DKK 11.8bn of grants in 2025[34][36].
Why the bear case holds
- Lilly overtook Novo to ~60% of the GLP-1 market; Mounjaro alone did $8.66bn in one quarter[20][21].
- CagriSema (22.7%) undershot the ~25% hoped for, and a semaglutide Alzheimer's trial failed[27][28][32].
- A US pricing reset toward ~$245/month and a semaglutide patent cliff (2026 abroad, ~2032 US)[60][59].
- Concentration: semaglutide is ~2/3 of sales, and the stock is down ~50% with 9,000 jobs cut[62][55].
A century of peptides, then five years that changed everything
Novo Nordisk's modern story is short and violent — but it rests on a hundred-year manufacturing base that competitors cannot quickly replicate.
Novo Nordisk is two companies in one timeline: a 100-year insulin-and-peptide maker with deep manufacturing expertise, and a 2017–2026 obesity-drug phenomenon. The first explains why it could scale GLP-1 supply; the second explains both its 2024 peak and its 2025–26 reversal[2][13].
From Toronto to Bagsværd
Novo Nordisk's roots run to the discovery of insulin. In 1923, Nobel laureate August Krogh brought the rights to make insulin to Denmark and, with diabetes physician Hans Christian Hagedorn, founded Nordisk Insulinlaboratorium[1]. A breakaway, Novo, formed in 1925; the two competed until merging in 1989into Novo Nordisk A/S, then the world's largest insulin producer[2]. For most of its history, Novo was a respected but unspectacular diabetes-care company — the kind of steady compounder its foundation owner was designed to hold.
The semaglutide decade
Everything changed with semaglutide, a GLP-1 receptor agonist. Approved as Ozempic for diabetes in December 2017, then as oral Rybelsus in 2019 and — decisively — as Wegovy for obesity in June 2021[3], it turned a metabolic-disease company into the central player in the biggest pharmaceutical launch story in a generation. By 2024 Novo was briefly the most valuable listed company in Europe[54].
The turn
The reversal was just as fast. In December 2024 the next-generation CagriSema posted 22.7% weight loss — strong in absolute terms, but below the ~25% investors had priced in — and the stock fell sharply[27][28]. Over 2025 Eli Lilly pulled ahead, Novo cut guidance, replaced its CEO with Mike Doustdar (its first non-Dane), announced 9,000 job cuts, and saw its Foundation owner take direct control of the board[5][6][44].
Milestones
- 1923Insulin comes to DenmarkAugust Krogh and Hans Christian Hagedorn found Nordisk Insulinlaboratorium after Krogh secures rights from Toronto's insulin pioneers[1].
- 1925A rival is bornFormer Nordisk employees, the Pedersen brothers, start Novo Terapeutisk Laboratorium — the two Danish insulin houses will compete for decades[2].
- 1989Novo + Nordisk mergeThe two combine into Novo Nordisk A/S, then the world's largest insulin producer, headquartered in Bagsværd[2].
- 2017Ozempic launchesInjectable semaglutide is approved in the US for type 2 diabetes — the molecule that will define the next decade[3].
- 2019Rybelsus — oral semaglutideThe first oral GLP-1 reaches the market for diabetes, proving the peptide can be taken as a pill[3].
- 2021Wegovy opens the obesity eraHigher-dose semaglutide is approved for weight management, igniting unprecedented demand[3].
- 2024
- Aug 2025
- Nov 2025
- Dec 2025–2026
A vast, under-treated disease base — and a market whose size is genuinely contested
Diabetes and obesity together affect well over a billion people. The open question is not demand but how much of it converts to paid prescriptions at sustainable prices.
The clinical opportunity is enormous — 589 million adults live with diabetes and more than 1 billion with obesity[8][9] — but analysts disagree sharply on the addressable market: estimates for anti-obesity drugs run from roughly $95bn to $130bn+ by 2030, and Goldman Sachs has both raised and cut its number[10][12]. Novo's fortunes ride on which end proves right.
The disease base
The International Diabetes Federation estimates 589 million adults (about 1 in 9) live with diabetes as of 2025, with more than 250 million undiagnosed and total cases projected to reach 853 million by 2050; over $1 trillion was spent on diabetes in 2024[8]. Obesity is larger still: the WHO and obesity bodies put the number of adults with obesity above 1 billion — roughly 16% of adults — and rising[9]. This is the demand reservoir GLP-1 drugs tap.
How big is the money, really?
Demand is not the same as a payable market. Forecasts for anti-obesity medication have swung widely: Goldman Sachs projected the market could reach $100bn by 2030, later lifted that to $130bn, then cut it back toward $95bn as it weighed access, adherence and pricing[10][12]. Morgan Stanley is more bullish, sizing the broader GLP-1 market at roughly $190bn by 2035[11]. The spread itself is the point: even sophisticated houses cannot agree whether the obesity market is a $95bn or a $190bn opportunity, because so much depends on insurance coverage and price.
Different definitions (anti-obesity vs all GLP-1) and dates; shown to illustrate the range, not a single comparable series[10][11][12].
A regulated, payer-driven industry
GLP-1 economics are decided less by patients than by payers: US pharmacy-benefit managers and Medicare, European health systems, and government formularies. That structure — high list prices, deep negotiated rebates, variable obesity coverage — means a drug can be in massive clinical demand while its realized price falls, exactly the squeeze now arriving via the 2025 US pricing deal (see Risks)[60].
One molecule, two diseases, world-class margins — and a vertically integrated supply chain
Novo makes money by selling patent-protected peptides at high gross margins, increasingly for obesity, and by owning the hard-to-build manufacturing that lets it supply them.
Novo's model is enviably simple and enviably profitable: in FY2025 it earned ~81% gross margin and DKK 128bn operating profit (~41% margin) on DKK 309bn of sales[13][15]. But the same numbers carry the warning — gross margin fell from 84.7% to 81.0% year-on-year, the first visible sign that pricing and competition are biting[15].
Where the revenue comes from
Novo reports three therapy areas. Diabetes care remains the largest at DKK 207bn (up 4% at constant currency), led by Ozempic at DKK 127bn; obesity care is the growth engine at DKK 82bn (+31% CER), almost all of it Wegovy; and rare disease (haemophilia, growth disorders) adds DKK 20bn[13][14]. Geographically, US Operations grew 8% and International Operations 14% at constant currency in 2025[16].
- Diabetes care — 207 — 67%
- Obesity care — 82 — 27%
- Rare disease — 20 — 6%
Source: Novo Nordisk Annual Report 2025[13]. Note that a single molecule, semaglutide (Ozempic + Rybelsus + Wegovy), spans the two largest slices.
The economics: high margin, now compressing
Patent-protected peptides carry exceptional margins. Yet 2025 showed the model is not immune: gross margin slipped to 81.0% (from 84.7%), operating profit was flat-to-down in kroner (DKK 128bn, −1%), and ~DKK 8bn of one-off restructuring weighed on the reported result even as constant-currency operating profit rose 6%[15][18]. Net profit was DKK 102bn[15]. Analysts summarized the year as strong numbers “overshadowed by a negative 2026 outlook”[18].
Owning the supply chain
A defining feature of Novo's model is that it makes what it sells. To break the Wegovy supply bottleneck, parent Novo Holdings bought contract manufacturer Catalent for ~$16.5bn in 2024 and sold three fill-finish plants to Novo Nordisk for $11bn[17]. This vertical integration is expensive but is a genuine barrier: sterile fill-finish capacity for injectables is scarce and slow to build.
Novo invented the category; Eli Lilly is winning it
The GLP-1 market has become a two-horse race in which the horse that started behind is now ahead — with a wave of challengers and cheap copies behind both.
Novo created the obesity-drug market, but Eli Lilly's tirzepatide is more potent on weight loss and has taken the lead — roughly 60% of the GLP-1 market, with Mounjaro alone at $8.66bn in a single quarter (+125%)[20][21]. Novo's counter is efficacy positioning (Wegovy's ~14% weight loss vs ~11% for Lilly's pill) and a ~65% share of new US category prescriptions[23] — a strong #2, not a leader.
The rivalry, in numbers
The decisive fact of 2025–26 is that Lilly overtook Novo. Lilly's tirzepatide franchise (Zepbound for obesity, Mounjaro for diabetes) brought in a combined $10.1bnin Q3 2025 — up from $4.37bn a year earlier — and tirzepatide became the world's best-selling drug, surpassing Keytruda[21]. By 2026 Lilly controlled roughly 60% of the GLP-1 market[20]. Novo's rebuttal is clinical: in the same coverage the Wegovy pill is cited at ~14% average weight loss versus ~11%for Lilly's orforglipron at the high dose, and Wegovy held ~65% of new US category scripts in early 2026[23].
Lilly also leads on convenience: its oral pill, orforglipron (Foundayo), does not need to be taken on an empty stomach — unlike the Wegovy pill — a difference Lilly stresses in marketing[25]. And behind the duopoly sit well-funded challengers — Amgen's MariTide, Viking's VK2735, and obesity assets in-licensed by Roche, Merck and AbbVie — plus the cheap compounded semaglutide that drew ~1 million Americans during the shortage[24][26].
Porter's Five Forces — a structurally attractive industry getting harder
Click each force for the rating and the evidence behind it.
Positioning: efficacy vs. oral convenience
The market is sorting on two axes that matter to patients and payers — how much weight a drug takes off, and how convenient it is (especially as a pill). Novo's injectables lead on efficacy, but Lilly is pressing on both fronts at once. Hover a point for the basis.
Wegovy (Novo): Semaglutide 2.4mg; ~15% weight loss, strong SELECT cardiovascular data; injectable plus a newer oral version.
Novo's competitive strengths
Out-innovate, go oral, expand the label — and bet the pipeline
Novo's strategy to regain ground rests on a pill franchise, next-generation molecules, and pushing semaglutide into new diseases. The moats are real; the question is whether they out-run Lilly.
Novo's durable advantages are peptide manufacturing at scale, a century of regulatory and clinical know-how, the cardiovascular evidence behind Wegovy, and a foundation owner that supplies patient capital[4][17][34]. Its strategy is to convert those into a next-generation lead via the oral pill, amycretin and CagriSema — but the headline CagriSema result undershot expectationsand an Alzheimer's bet failed[28][32].
The stated strategy
The playbook has three moves. First, own oral GLP-1: the Wegovy pill launched ahead of Lilly's and drove a 2026 guidance raise[7][29]. Second, next-generation molecules: amycretin, a GLP-1/amylin agonist in oral and injectable forms, advanced to late-stage trials in late 2025, and CagriSema was filed with the FDA in December 2025[30][29]. Third, expand the label: Novo is pushing semaglutide into cardiometabolic indications and presenting new data at major congresses[31].
The revealed strategy — and its stumbles
What Novo actually delivered in 2024–25 was more mixed. CagriSema's 22.7% weight loss was superior to its components but below the ~25% the market wanted, and the company noted only 57% of patients reached the top dose[27][28]. A Phase 3 trial of semaglutide in early Alzheimer's disease failed to show benefit, and Novo lost a bidding war for obesity biotech Metsera to Pfizer[32][33]. The pipeline is deep, but the recent batting average has fed the bear case.
“We are encouraged by the weight loss profile of CagriSema demonstrating superiority over both semaglutide and cagrilintide in monotherapy in the REDEFINE 1 trial. This was achieved even though only 57% of patients reached the highest CagriSema dose.”
The moats
Strengths
Weaknesses
Opportunities
A charitable foundation controls Novo — and Novo, in turn, shapes Denmark
The Novo Nordisk Foundation holds ~77% of the votes and must keep control. That structure gives patient capital and philanthropy — and, critics say, a concentration of power and a country dangerously dependent on one company.
Through Novo Holdings, the Novo Nordisk Foundation held about 28.1% of the share capital but 77.3% of the votes at end-2025 — via A shares carrying 10× voting power — and is obligated to maintain control[34]. That makes Novo unusually insulated from takeover and short-term pressure, but in 2025 it also let the Foundation take direct command of the board, a move Danish commentators called a “power demonstration”[46].
The ownership machine
Novo Nordisk sits inside an unusual structure. The Novo Nordisk Foundation owns Novo Holdings, which holds the controlling stake in both Novo Nordisk and the enzymes company Novonesis. At end-2025 that stake was about 28.1% of Novo Nordisk's capital but 77.3% of the votes, because unlisted A shares carry ten times the votes of ordinary B shares; the Foundation is bound by its articles to keep control[34]. Novo Holdings reported DKK 694bn (EUR 93bn) of assets under management, and the Foundation — reported around $220bnin early 2026 — is the world's wealthiest charitable foundation[35]. It recycled dividends into DKK 11.8bn of grants in 2025, its largest year[36].
Danish coverage captures the scale: during 2023 the Foundation's wealth surpassed both the Gates Foundation and the Wellcome Trust[37].
“The Foundation's wealth has now also surpassed both the Bill and Melinda Gates Foundation and the British Wellcome Trust.”
The “Novo economy”
Novo is so large relative to Denmark that it distorts the national picture. Economist Lars Christensen estimated that, stripping out pharma, Danish real GDP would have shrunk 0.3% in a period it actually grew 1.7%[39]. Economists warn this dependence is a risk as much as a blessing.
“But it can become unhealthy if we live at Novo's mercy. If you're not careful, a single company can distort the picture of how the Danish economy is actually doing.”
The dependence even reaches public accounting: asked in late 2025 to quantify Novo's GDP effect, Denmark's finance ministry declined “for confidentiality reasons,” while disclosing that Novo Holdings paid DKK 15.3bn in corporate tax for 2023[40].
Leadership upheaval and the 2025 board coup
The strategic crisis triggered a governance one. New CEO Mike Doustdar — the first non-Dane to lead Novo — announced ~9,000 job cuts (about 5,000 in Denmark), targeting “duplicates and dual functions”[41][72]. The union Djøf called the process “chaotic and opaque”[42], and the outgoing CEO conceded a crisis of confidence.
“I think we are in a crisis of confidence, because we have downgraded. We have disappointed several times in short succession, and that is reflected in the share price.”
Then, in October–November 2025, nearly the entire board departed early after the Foundation and the board could not agree, and former CEO Lars Rebien Sørensen was installed as chair — framed as a temporary, two-to-three-year role[73][44][45]. Critics saw an extraordinary concentration of power: the same person now effectively chairs both Novo Nordisk and its controlling owner[74].
“Lars Rebien has thrown a hand grenade into the boardroom. The same person sits at the head of the table in the boardroom for both Novo Nordisk and the owner-foundation.”
Stripping out the Foundation's votes, only 38.7% of ordinary shareholders backed Sørensen as chair, underscoring the gap between the controlling owner and minority investors[47].
The case for the structure
Still elite on margins — but lapped on growth and valued like a laggard
Against Eli Lilly, Roche and AstraZeneca, Novo remains one of pharma's most profitable companies. The market, though, now prices it as the one that fell behind.
Novo's ~41% operating margin is among the best in large-cap pharma[51], but Eli Lilly is both bigger and far faster-growing — FY2025 revenue around $65bn (+45%) versus Novo's ~$48bn — and is valued at roughly 5×Novo's market cap[48][54]. The peer set frames the core tension: a superb business that the market treats as a loser.
Scale and growth
On the metrics that matter for a drug maker — revenue, growth, profitability and valuation — Novo is a strong but no longer leading large-cap. Lilly's tirzepatide engine pushed FY2025 revenue to about $65bn, up ~45%[48]; Roche reported CHF 61.5bn (+7% CER) and AstraZeneca about $58.7bn[49][50]. Novo's DKK 309bn is roughly $48bn, growing 10% at constant currency[13].
*Roche group sales CHF 61.5bn convert to a higher US$ figure; figures span different fiscal calendars and currencies and are directional, not precisely comparable[49][48][50].
The valuation gap
The starkest contrast is market value. Novo is worth about $186bnas of mid-2026 versus Eli Lilly's roughly $950bn— and by Q1 2026 Lilly's Mounjaro alone ($8.66bn in a quarter, +125%) was approaching the size of Novo's entire quarterly adjusted sales (~DKK 70bn)[54][52].
Benchmark table
| Company | FY2025 revenue | Growth | Note |
|---|---|---|---|
| Eli Lilly | ~$65B | ~+45% | GLP-1 leader; ~$950B market cap[48][54] |
| Roche | CHF 61.5B | +7% CER | Diversified pharma + diagnostics[49] |
| AstraZeneca | ~$58.7B | ~+9% | Oncology-led portfolio[50] |
| Novo Nordisk | DKK 309B (~$48B) | +10% CER | ~41% op margin; ~$186B market cap[13][51][54] |
Currencies and fiscal calendars differ; treat as directional. Market caps are point-in-time as of mid-2026.
A cash machine whose stock crashed faster than its business
Novo still earns over DKK 100bn a year. But the equity story turned violently in 2024–26 as growth decelerated and the market re-rated the whole obesity thesis.
The disconnect is the story: FY2025 sales rose 10% at constant currency to DKK 309bn and net profit 1% to DKK 102bn[53], yet the shares fell about 48% in 2025 and the market value dropped to roughly $186bn — around a fifth of Eli Lilly's[55][54]. The business decelerated; the stock collapsed.
The income statement is still strong
On fundamentals Novo remains formidable: DKK 309bn of FY2025 sales (+10% CER), DKK 128bn operating profit, and DKK 102bn net profit[53][15]. The trajectory below shows a franchise that roughly tripled in five years and is still growing — just no longer at boom-era rates.
2025 from the annual report[53]; 2021–2024 are approximate reported annual totals shown for trajectory (see Methodology).
The stock told a different story
From a 2024 peak that briefly made it Europe's most valuable listed company, Novo's shares fell about 48% in 2025 and hit a four-year low below $44, cutting its market value to roughly $186bn by mid-2026[55][54]. The drop reflected a cascade: the CagriSema disappointment, repeated guidance cuts, Lilly's gains, and finally a 2026 outlook for declining adjusted sales[57]. Danish markets felt it acutely on the February 2026 results.
“The share fell 18 percent at the opening of the Danish stock exchange today ... if you look back to June 2024, when the share peaked, there has been a fall of over 70 percent.”
2026: a guided decline, then a small reprieve
For 2026 Novo guides adjusted sales and operating profit to fall 4%–12% at constant currency — an improvement on the earlier −5% to −13% after a stronger-than-expected Wegovy-pill launch; Q1 2026 adjusted sales were already down 4%[57]. The company continues to return cash, proposing a dividend of DKK 11.70 per share for 2025[58].
A pricing reset, a patent cliff, a single molecule — and a watchful public
Novo's biggest risks are not demand but realized price, patent duration, concentration, and the reputational scrutiny that comes with selling a blockbuster to whole populations.
The clearest threats are structural: a US deal pushing obesity-drug prices toward $245/month[60], a semaglutide patent cliff already opening abroad (US protection to ~2032)[59], and ~two-thirds of sales riding on one molecule[62]. Safety scares have so far not been substantiated — the EMA found no suicidality link[61] — but pricing, patents and concentration are real and converging.
1 · Pricing pressure, at home and abroad
In November 2025 the Trump administration struck deals with Novo and Lilly to cut US obesity-drug prices: about $245 a month under Medicare/Medicaid, roughly $350 (trending to $245) in cash via TrumpRx, and ~$149–150 starting doses for the pills[60]. Lower realized prices on huge volumes is the central margin risk. The pressure is visible in Denmark too, where an Ozempic pen has cost far more than in neighbouring Norway.
“The same Ozempic pen with four doses suitable for a month's use currently costs 975 kroner in Denmark ... and only 549 Danish kroner in Norway.”
Danish reporting has also scrutinized Novo's pricing tactics: documents showed Novo would file lower prices only once the Medicines Agency signalled it would keep a general subsidy — which a Cochrane professor called “a pure confession”[64].
2 · The semaglutide patent cliff
Patents are a wasting asset. Semaglutide protection lapsed in Canada in early 2026 (after a missed maintenance fee) and expires around 2026 in markets such as India and China, where generics are already launching; US protection runs to roughly 2032[59]. As cheap copies spread abroad, Novo must migrate patients to next-generation, still-patented molecules before its flagship erodes.
3 · Substitution and compounding
During the 2023–25 shortage, roughly one million Americans turned to cheaper compounded semaglutide, and challengers (Amgen, Viking, Roche-backed assets) are advancing[26][24]. Even with the official shortage resolved, the episode showed how quickly volume can leak to substitutes.
4 · Concentration risk
Semaglutide (Ozempic + Rybelsus + Wegovy) is roughly two-thirds of sales, so any clinical, patent or pricing shock is magnified[62]. The failed Alzheimer's trial is a reminder that label-expansion bets can miss[32].
5 · Safety and reputation
GLP-1 safety has drawn scrutiny — gastrointestinal effects, and a 2023–24 review of suicidality concerns. Crucially, the EMA's safety committee concluded in April 2024 that there was no evidencelinking GLP-1 medicines to suicidal thoughts and recommended no label change — a point in Novo's favour[61]. But reputational risk persists: Danish critics describe the Foundation's pervasive health-sector funding as “a Trojan horse,” question research independence, and have challenged Novo on local environmental permits[66][65][67].
Why the risks bite
Three ways the next few years could run
These are possibilities to weigh, not a prediction. Novo's future turns on execution against Lilly, the oral and next-gen pipeline, and how hard pricing and patents bite.
The decisive variables are few and knowable: can the oral and next-gen pipeline out-run Lilly, how fast does the pricing-and-patent reset cut realized revenue, and does the obesity market grow into the bullish or the bearish forecast. Reasonable analysts land in different places — Morningstar sees value, others see a value trap[68][69].
Bull · Base · Bear
The pipeline re-accelerates the franchise
Oral Wegovy and amycretin scale, CagriSema is approved, and label expansions widen the market; cost cuts restore margin and the depressed multiple re-rates. Morningstar already views the shares as undervalued after the collapse[68][30].
Watch: oral-pill uptake, amycretin Phase 3 data, and whether 2026 sales beat the guided decline[57].
A strong #2 in a growing duopoly
Novo holds a durable second place; sales are roughly flat-to-modest in 2026 then resume growth as the obesity market expands. Margins reset lower on pricing, but the company stays highly profitable — just no longer the growth darling[57][23].
Watch: realized US prices post-TrumpRx, and whether Wegovy holds ~65% of new category scripts[60][23].
Lilly's lead compounds; the cliff arrives first
Lilly's efficacy and oral-convenience edge widen its share; the pricing reset and 2026 generics erode semaglutide faster than the pipeline ramps; concentration bites and the multiple stays compressed. S&P framed Lilly's overtaking as structural[70][59].
Watch: GLP-1 share trend, generic launches abroad, and any further pipeline setbacks[20][59].
What would change the picture
The clearest near-term tells are: the oral-pill ramp (already strong enough to lift 2026 guidance)[71]; amycretin and CagriSema readouts and approvals[30]; the GLP-1 share trend versus Lilly[20]; and the pace of price cuts and generic entry[60][59]. None of these is a mystery — they are scheduled trials, launches and policy steps a reader can track.
How this was made, and where it may be wrong
A research compilation is only as good as its honesty about its own limits. Here is the method, the framework set, and the claims to treat with caution.
Method
Research proceeded by fan-out web search across eleven question areas and direct fetching of primary and reputable secondary sources. Novo Nordisk's annual report and company announcements, the Novo Nordisk Foundation and Novo Holdings pages, and regulators (FDA, EMA, IDF) were preferred, followed by reputable secondary press (Reuters/CNBC/BioPharma Dive/Fierce Pharma, Goldman Sachs and Morgan Stanley research) and, importantly, a substantial Danish-language pass. Every URL cited on the Sources page was opened and read during research; no link was reconstructed from memory. Each claim was transcribed into a structured manifest tagged with a tier (1–3), a confidence level, a stance, and a language — 74 sources in all (16 Tier-1, 57 Tier-2, 1 Tier-3; stance mix 15 supporting / 34 critical / 25 neutral; ~26% Danish-language). The load-bearing figures are FY2025 sales of DKK 309bn and net profit of DKK 102bn, Lilly's ~60% GLP-1 share, the ~$186bn vs ~$950bn market-cap gap, the Foundation's 77% voting control, and the 2026 guided decline.
Native-language research
Because Novo Nordisk's home market is Denmark, English-only coverage would miss the domestic debate — over the Foundation's power, the “Novo economy,” the layoffs, drug pricing and the November 2025 board takeover. Roughly a quarter of sources are Danish (DR, TV 2, Altinget, Økonomisk Ugebrev, Fagbladet 3F, Djøfbladet, Information, Ingeniøren). Danish quotes are shown in the original with an English translation alongside; figures were reconciled (mia. = billion, mio. = million), and the Foundation's ~$220bn net worth is kept distinct from Novo Holdings' DKK 694bn assets under management[35].
Frameworks used
The analysis applies the Pyramid Principle for answer-first synthesis, Porter's Five Forces to read industry structure, peer benchmarking against Eli Lilly, Roche and AstraZeneca, a SWOT to organize internal and external factors, a 2×2 positioning map of efficacy versus oral convenience, segment economics by therapy area and geography, and bull/base/bear scenarios for the forward view. BCG growth-share, Ansoff and the McKinsey 7S model were skipped because the clean, non-decorative data they require was not available here.
Disclosed vs. estimated
Disclosed figures are those Novo itself reports — therapy-area and product sales, operating and net profit, margins, R&D, dividend. Directional figures include market forecasts (Goldman/Morgan Stanley, which span different definitions and dates), peer revenues converted across currencies and fiscal calendars, GLP-1 market-share readings, and market caps. The Foundation's net-worth figure is a secondary estimate.
- The FY2021–2024 sales trajectory is approximate. Only FY2025 is taken directly from the annual report[13]; earlier years are rounded reported totals shown to illustrate the slope — confirm against Novo's filings for publication use.
- Market caps and the “~50% / ~70% from peak” figures are point-in-time and source-dependent. Different providers show different peak values (e.g. a 2023 USD high vs a mid-2024 peak); USD/DKK conversion adds noise[54][55][56].
- GLP-1 “~60% share” mixes US and global, list vs script measures. Treat the Lilly-vs-Novo share figures as directional[20][55].
- Obesity-market forecasts disagree by ~2× ($95bn–$190bn) and use different definitions and horizons[10][11][12].
- Wegovy's FY2025 sales and the ~two-thirds semaglutide concentration are derived from segment/product disclosures, not a single Novo-reported “semaglutide total”[14][62].
- Some sources blocked automated fetching or are paywalled (certain wire releases, an Ingeniøren PRO article); where so, claims rely on the fetched portion or independently corroborated reporting.
- This is point-in-time. Figures are as of June 4, 2026; the oral-pill ramp, CagriSema/amycretin readouts, US pricing implementation, patent litigation and the board transition are all still moving[57][45].
Neutrality & independence
This is a compilation, not an argument: each section pairs the case for and the case against, so supporting and critical evidence sit side by side and you can reach your own conclusion. The study is not affiliated with Novo Nordisk and is point-in-time as of June 4, 2026.
Full bibliography
Every load-bearing claim on this site links here. Each source was fetched during research; grouped by section, with tier, stance, confidence and language shown. Danish-language sources include the original text.
Company & Timeline
Novo Nordisk traces to 1923, when August Krogh and Hans Christian Hagedorn founded Nordisk Insulinlaboratorium to make insulin in Denmark after Krogh obtained rights from Toronto.
“Nordisk Insulinlaboratorium ... was founded in 1923 ... August Krogh ... received permission to manufacture insulin in the Nordic countries.”
https://en.wikipedia.org/wiki/Novo_NordiskNovo (founded 1925 by the Pedersen brothers) and Nordisk competed for decades before merging in 1989 to form Novo Nordisk A/S, then the world's largest insulin producer, headquartered in Bagsværd.
“Novo and Nordisk ... merged in 1989 to become Novo Nordisk A/S, the world's largest producer of insulin.”
https://en.wikipedia.org/wiki/Novo_NordiskSemaglutide reached the market as Ozempic (injectable, type 2 diabetes) in Dec 2017, Rybelsus (oral diabetes) in Sept 2019, Wegovy (obesity) in June 2021, and an oral Wegovy for weight management in Dec 2025.
“In December 2017, the injectable version with the brand name Ozempic was approved ... In June 2021 ... Wegovy ... approved by the FDA as an anti-obesity medication.”
https://en.wikipedia.org/wiki/SemaglutideIn the 17,604-patient SELECT trial, semaglutide cut major adverse cardiovascular events by 20%; the FDA added a cardiovascular risk-reduction indication to Wegovy on March 8, 2024.
“semaglutide treatment resulted in a 20% reduction in MACE compared to placebo.”
https://www.tctmd.com/news/fda-grants-mace-reduction-indication-semaglutide- [5]Maziar Mike Doustdar appointed as president and CEO of Novo Nordisk — GlobeNewswireTier 1neutralHigh confidence
Maziar (Mike) Doustdar became president and CEO on August 7, 2025 — the first non-Dane to lead the company since 1923 — succeeding Lars Fruergaard Jørgensen.
“Mike Doustdar ... appointed as president and chief executive officer, effective 7 August 2025 ... succeeds Lars Fruergaard Jørgensen.”
https://www.globenewswire.com/news-release/2025/07/29/3123141/0/en/Maziar-Mike-Doustdar-appointed-as-president-and-chief-executive-officer-of-Novo-Nordisk.html - [6]Novo Nordisk to lay off 9,000 workers in major restructuring — BioPharma DiveTier 2criticalHigh confidence
On Sept 10, 2025 Novo Nordisk announced ~9,000 job cuts (about 11% of ~78,400 staff, ~5,000 in Denmark) to deliver ~DKK 8bn of annual savings, amid GLP-1 competition.
“Novo Nordisk ... will cut about 9,000 jobs ... around 5,000 in Denmark ... expects to save 8 billion kroner ... by the end of 2026.”
https://www.biopharmadive.com/news/novo-nordisk-layoffs-restructuring-obesity-drug-competition/759748/ - [7]FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss — AJMCTier 2supportingHigh confidence
In December 2025 the FDA approved oral semaglutide (Wegovy pill) — the first oral GLP-1 for weight loss; the pill launched in the US in early 2026.
“FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss”
https://www.ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss - [80]Nyt kanonregnskab: Novo Nordisk runder for første gang 100 milliarder på bundlinjen — DRTier 2neutralHigh confidence
At the prior peak, Novo passed DKK 100bn of net profit for the first time on FY2024 results: revenue ~DKK 290bn (+25%) and net profit DKK 101bn, with Wegovy at DKK 58bn (+86%).
“Revenue rounded 290 billion kroner last year, while profit after tax landed at 101 billion kroner.”original · da:“Omsætningen rundede 290 milliarder kroner sidste år, mens overskuddet efter skat landede på 101 milliarder kroner.”
https://www.dr.dk/nyheder/penge/nyt-kanonregnskab-novo-nordisk-runder-foerste-gang-100-milliarder-paa-bundlinjen
Market & Industry Structure
The IDF estimates 589 million adults (11.1%, ~1 in 9) lived with diabetes in 2025, rising to 853 million by 2050; over USD 1 trillion was spent on diabetes in 2024.
“An estimated 589 million adults aged 20–79 years are living with diabetes — 11.1% of all adults.”
https://idf.org/about-diabetes/diabetes-facts-figures/Roughly 1 billion+ adults — about 16% of the world's adults — are estimated to live with obesity, a number projected to keep rising toward 2030.
“In 2022, 1 in 8 people in the world were living with obesity ... adult obesity has more than doubled since 1990.”
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight- [10]Why the anti-obesity drug market could grow to $100 billion by 2030 — Goldman SachsTier 2supportingMedium confidence
Goldman Sachs Research projected the anti-obesity-medication market could grow to roughly $95–130bn by 2030 (forecasts revised over 2023–2025).
“the market for anti-obesity medications ... could grow to $100 billion by 2030.”
https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market - [11]GLP-1 Market Expected to More Than Double to $190B by 2035 — Morgan StanleyTier 2supportingMedium confidence
Morgan Stanley Research forecasts the global GLP-1 market could reach roughly $190bn by 2035, more than double 2025 levels.
“the global market for GLP-1 drugs could reach $190 billion by 2035.”
https://www.morganstanley.com/insights/articles/glp1-weight-loss-market-may-double-190-billion-2035 - [12]The anti-obesity drug market may prove smaller than expected — Goldman SachsTier 2criticalMedium confidence
Goldman Sachs later cautioned the obesity-drug market may prove smaller than its bullish case, cutting its 2030 estimate (to ~$95bn from $130bn) on access, adherence and pricing.
“The anti-obesity drug market may prove smaller than expected.”
https://www.goldmansachs.com/insights/articles/the-anti-obesity-drug-market-may-prove-smaller-than-expected
Business Model & Segment Economics
FY2025 sales were DKK 309,064m (+6% in DKK, +10% at constant exchange rates): Diabetes care DKK 207,109m (+4% CER), Obesity care DKK 82,347m (+31% CER), Rare disease DKK 19,608m.
“Sales increased by 6% measured in Danish kroner and by 10% at CER ... Obesity care ... 31% at CER ... Diabetes care ... 4% at CER.”
https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.htmlOzempic was Novo's largest product at DKK 127,089m in 2025 (+10% CER); Wegovy reached DKK 79,106m and Rybelsus DKK 22,093m (−2% CER); the obesity portfolio served 3.6 million people.
“Ozempic ... DKK 127,089 million ... Rybelsus ... DKK 22,093 million.”
https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.htmlGross margin fell to 81.0% in 2025 (from 84.7% in 2024); operating profit was DKK 127,658m (−1% in DKK, +6% CER), net profit DKK 102,434m (+1%), and R&D DKK 52,039m (+8%).
“Gross margin ... 81.0% ... Operating profit ... DKK 127,658 million ... Net profit ... DKK 102,434 million.”
https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.htmlBy geography, FY2025 US Operations grew 3% (8% CER) and International Operations 10% (14% CER); CEO Doustdar previously built International Operations to ~DKK 112bn in 2024.
“International Operations have more than doubled sales to approximately DKK 112 billion in 2024.”
https://www.globenewswire.com/news-release/2025/07/29/3123141/0/en/Maziar-Mike-Doustdar-appointed-as-president-and-chief-executive-officer-of-Novo-Nordisk.htmlTo secure fill-finish capacity, Novo Holdings bought Catalent for ~$16.5bn (closed Dec 2024) and sold three fill-finish sites (Italy, Indiana, Belgium) to Novo Nordisk for $11bn.
“Novo Holdings ... acquire Catalent ... $16.5 billion ... Novo Nordisk ... acquire three of Catalent's fill-finish sites ... for $11 billion.”
https://www.biopharmadive.com/news/novo-catalent-acquire-deal-wegovy-manufacturing-obesity/706530/- [18]Novo Nordisk FY2025 slides: Strong results overshadowed by negative 2026 outlook — Investing.comTier 2criticalMedium confidence
Analysts framed Novo's FY2025 print as 'strong results overshadowed by a negative 2026 outlook'; ~DKK 8bn of one-off restructuring costs weighed on reported operating profit.
“Strong results overshadowed by negative 2026 outlook.”
https://www.investing.com/news/company-news/novo-nordisk-fy-2025-slides-strong-results-overshadowed-by-negative-2026-outlook-93CH-4484958 - [19]Novo Nordisk Q1 2026 earnings beat on Wegovy pill demand — Yahoo FinanceTier 2neutralHigh confidence
In Q1 2026, reported sales were DKK 96.8bn (+24%, inflated by a one-time non-cash reversal); adjusted sales of DKK 70.1bn fell 4% at CER and adjusted operating profit DKK 32.9bn fell 6%.
“Reported first-quarter net sales reached 96.82 billion kroner ... injectable version of Wegovy posted a 12% ... gain, reaching 18.2 billion kroner ... Ozempic fell 8%.”
https://finance.yahoo.com/sectors/healthcare/articles/novo-nordisk-q1-2026-earnings-114019111.html - [76]Novo Nordisk præsenterer stort overskud i regnskab for første kvartal af 2026 — Dagens PharmaTier 2neutralHigh confidence
Danish trade press explained that Novo's headline Q1 2026 sales jump was driven by a reversed provision originally booked for possible US drug rebates — i.e. an accounting one-off, not underlying growth.
“The increased sales result from a reversed provision originally made to account for possible discounts on pharmaceuticals in the American market.”original · da:“Det øgede salg skyldes en tilbageført hensættelse, der oprindeligt blev foretaget for at tage højde for mulige rabatter på lægemidler på det amerikanske marked.”
https://www.dagenspharma.dk/nyheder/overblik/novo-nordisk-praesenterer-stort-overskud-i-regnskab-for-forste-kvartal-af-2026/
Competitive Landscape & Positioning
- [20]Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125% — 24/7 Wall St.Tier 2criticalHigh confidence
Eli Lilly has come to control roughly 60% of the GLP-1 market; its Mounjaro generated $8.66bn in Q1 2026 alone, up ~125% year over year.
“Eli Lilly ... controls 60% of the GLP-1 market ... Mounjaro generated $8.66 billion in quarterly revenue ... a 125% year-over-year increase.”
https://247wallst.com/investing/2026/05/04/eli-lilly-captures-60-of-the-glp-1-market-as-mounjaro-revenue-soars-125/ - [21]Lilly hikes revenue forecasts on booming obesity drug sales — BioPharma DiveTier 2criticalHigh confidence
Lilly's tirzepatide (Zepbound + Mounjaro) brought in a combined $10.1bn in Q3 2025 (from $4.37bn a year earlier) and became the world's best-selling drug, surpassing Keytruda.
“Zepbound and Mounjaro brought in a combined $10.1 billion ... became the world's best-selling drug in the third quarter.”
https://www.biopharmadive.com/news/lilly-third-quarter-2025-earnings-zepbound-mounjaro-obesity-sales/804232/ - [22]FDA approves Lilly obesity pill, triggering battle with Novo Nordisk — BioPharma DiveTier 2criticalHigh confidence
The FDA approved Lilly's oral pill orforglipron (Foundayo) on April 1, 2026, four months after Wegovy's pill; analysts project peak US sales up to ~$36bn, intensifying the oral-GLP-1 fight.
“The FDA approved Eli Lilly's obesity pill ... orforglipron ... brand name Foundayo ... arriving four months after Novo Nordisk's Wegovy pill.”
https://www.biopharmadive.com/news/fda-approves-lilly-obesity-pill-orforglipron-foundayo-novo/816359/ - [23]FDA approves Lilly obesity pill, triggering battle with Novo Nordisk — BioPharma DiveTier 2supportingMedium confidence
Novo argues efficacy still differentiates it: in the same coverage the Wegovy pill is cited at ~14% average weight loss vs ~11% for orforglipron at the high dose, and Wegovy held ~65% of new US category prescriptions in early 2026.
“Foundayo helped people with obesity ... lose approximately 11% ... By contrast, Wegovy achieved an average weight loss of 14%.”
https://www.biopharmadive.com/news/fda-approves-lilly-obesity-pill-orforglipron-foundayo-novo/816359/ Well-funded challengers are entering obesity: Amgen's MariTide (GLP-1/GIP-antagonist), Viking's VK2735 (in Phase 3), and in-licensing by Roche, Merck and AbbVie — though Novo and Lilly still dominate.
“VK2735 ... dual agonist of the GLP-1 and GIP receptors ... in development for ... obesity.”
https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2735/- [25]FDA approves Lilly obesity pill, triggering battle with Novo Nordisk — BioPharma DiveTier 2criticalHigh confidence
Lilly's once-daily orforglipron does not need to be taken on an empty stomach, a convenience edge Lilly emphasizes against the Wegovy pill's fasting requirement.
“Foundayo doesn't require an empty stomach, distinguishing it from Wegovy's requirement for fasting administration.”
https://www.biopharmadive.com/news/fda-approves-lilly-obesity-pill-orforglipron-foundayo-novo/816359/ - [26]Eli Lilly set to leapfrog Novo Nordisk in weight-loss drug race — S&P GlobalTier 2criticalMedium confidence
During the 2023–2025 semaglutide shortage, roughly one million Americans shifted to cheaper compounded semaglutide, pulling volume away from branded Wegovy/Ozempic.
“a rise in the use of compounded semaglutide amid ongoing shortages ... weighed on sales.”
https://www.spglobal.com/market-intelligence/en/news-insights/research/2025/08/eli-lilly-set-to-leapfrog-novo-nordisk-in-weight-loss-drug-race - [78]Betydningen af Novos stærke lancering af Wegovy-pillen — Økonomisk UgebrevTier 2supportingMedium confidence
Danish analysis called Novo's launch of the Wegovy pill 'very successful so far,' with over 1 million patients filled and ~80% new to obesity medicine — a counter to the Lilly-is-winning narrative.
“The launch of the Wegovy pill has been very successful so far.”original · da:“Lanceringen af Wegovy-pillen har været meget succesfuld indtil nu.”
https://ugebrev.dk/ledelse/tema-1-kvartalsregnskaber-betydningen-af-novos-staerke-lancering-af-wegovy-pillen/
Strategy, Pipeline & Moats
- [27]CagriSema demonstrates superior weight loss in the REDEFINE 1 trial — Novo NordiskTier 1neutralHigh confidence
Novo's next-gen CagriSema (cagrilintide + semaglutide) showed 22.7% weight loss at 68 weeks (trial-product estimand) in REDEFINE 1 — superior to each component but below the ~25% the market had anticipated.
“a weight loss of 22.7% was achieved ... compared to 2.3% with placebo ... only 57% of patients reached the highest CagriSema dose.”
https://www.globenewswire.com/news-release/2024/12/20/3000444/0/en/Novo-Nordisk-A-S-CagriSema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-in-the-REDEFINE-1-trial.html - [28]What Novo Nordisk's disappointing trial results mean for the obesity drug market — STATTier 2criticalHigh confidence
The CagriSema readout disappointed investors because it fell short of a ~25% weight-loss expectation; Novo shares fell sharply (around 20%+) on the December 2024 news.
“the results ... fell short of the 25% weight loss the company had previously set as its goal.”
https://www.statnews.com/2024/12/20/novo-nordisk-cagrisema-obesity-drug-market-impact/ Novo submitted CagriSema to the FDA in December 2025 (based on REDEFINE 1 and 2) and has an oral semaglutide 25mg obesity filing under review, with decisions expected in 2026.
“Novo Nordisk submitted a new drug application (NDA) to the FDA ... for CagriSema.”
https://www.pharmexec.com/view/novo-nordisk-submits-nda-fda-cagrisema- [30]Novo's next-gen obesity drug amycretin heads to late-stage testing — CNBCTier 2supportingHigh confidence
Novo's most-watched next-gen candidate, amycretin (a GLP-1/amylin agonist with oral and injectable forms), advanced to a late-stage program in late 2025 after early data showing meaningful weight loss.
“Novo Nordisk ... moves next-gen drug amycretin to late-stage diabetes trial after promising data.”
https://www.cnbc.com/2025/11/25/novos-next-gen-obesity-drug-shows-positive-results-heads-to-late-stage-testing.html - [31]Novo Nordisk advances cardiometabolic pipeline with new data at ADA 2026 — PR NewswireTier 2supportingMedium confidence
Novo is broadening semaglutide beyond weight loss and diabetes into cardiometabolic indications, presenting new CagriSema and pipeline data at the 2026 American Diabetes Association sessions.
“Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide.”
https://www.prnewswire.com/news-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions-302783110.html A late-2025 Phase 3 trial of semaglutide in early Alzheimer's disease (EVOKE) failed to show a statistically significant benefit — a setback to Novo's label-expansion thesis.
“the company's phase 3 trial testing semaglutide for Alzheimer's disease did not demonstrate a statistically significant reduction.”
https://www.fool.com/investing/2025/11/29/why-novo-nordisk-shares-just-hit-a-four-year-low/- [33]Why Novo Nordisk Stock Just Hit a Four-Year Low — The Motley FoolTier 2criticalMedium confidence
Novo lost a November 2025 bidding war for obesity biotech Metsera to Pfizer, a missed opportunity to bolster its next-generation pipeline.
“Novo Nordisk lost a bidding war for biotech startup Metsera to Pfizer in November 2025.”
https://www.fool.com/investing/2025/11/29/why-novo-nordisk-shares-just-hit-a-four-year-low/ - [82]Novo Nordisk får grønt lys til Wegovy-pille i Europa — Økonomisk UgebrevTier 2supportingMedium confidence
In May 2026 the EMA recommended approving an oral Wegovy for weight management in the EU — the first oral GLP-1 for weight loss in Europe — extending Novo's oral franchise beyond the US.
“The European Medicines Agency (EMA) recommended an expansion of the marketing authorization for Wegovy to also include an oral formulation for weight control.”original · da:“Det Europæiske Lægemiddelagentur (EMA) anbefalede en udvidelse af markedsføringsgodkendelsen for Wegovy til også at omfatte en oral formulering til vægtkontrol.”
https://ugebrev.dk/flashnews/danske-bank-novo-nordisk-faar-groent-lys-til-wegovy-pille-i-europa/
Ownership, the Foundation & Denmark
Novo Nordisk is controlled by the Novo Nordisk Foundation through Novo Holdings, which at end-2025 held ~28.1% of share capital but ~77.3% of votes via 10x-voting A shares; the Foundation is obligated to keep control.
“about 28.1% of the share capital and about 77.3% of the votes ... A shares have voting rights that are 10 times greater than those of the B (ordinary) shares.”
https://novonordiskfonden.dk/en/who-we-are/ownership/The Novo Nordisk Foundation is the world's wealthiest charitable foundation, reported at roughly USD 220bn in early 2026; its asset manager Novo Holdings reported DKK 694bn (EUR 93bn) of assets under management at year-end 2025.
“As of year-end 2025, Novo Holdings had Total Assets under Management of DKK 694 billion (EUR 93 billion) ... Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S.”
https://novoholdings.dk/about- [36]DKK 11.8 billion awarded to benefit people and the planet in 2025 — Novo Nordisk FoundationTier 1supportingHigh confidence
The Foundation awarded DKK 11.8bn (~EUR 1.6bn) in grants in 2025 — its largest year — funding research, health and climate, reinvesting dividends from its Novo Nordisk stake.
“DKK 11.8 billion (€1.6 billion) awarded to benefit people and the planet in 2025.”
https://novonordiskfonden.dk/en/news/dkk-11-8-billion-e1-6-billion-awarded-to-benefit-people-and-the-planet-in-2025 During 2023 the Foundation's wealth surpassed both the Gates Foundation and the Wellcome Trust, and Novo Nordisk's revenue surpassed all of Denmark's GDP, per Danish coverage.
“The Foundation's wealth has now also surpassed both the Bill and Melinda Gates Foundation and the British Wellcome Trust.”original · da:“Fondens formue har nu også passeret både Bill og Melinda Gates Foundation og britiske Wellcome Trusts.”
https://www.altinget.dk/fonde/artikel/novo-nordisk-fonden-gaar-paa-verdensscenen- [38]Novo Nordisks succes risikerer at gøre dansk økonomi 'usund', advarer professor — TV 2Tier 2criticalHigh confidence
Economist Michael Svarer (Aarhus University) warned that over-reliance on Novo can be 'unhealthy' and can distort the picture of how the Danish economy is really doing.
“But it can become unhealthy if we live at Novo's mercy ... If you're not careful, a single company can distort the picture of how the Danish economy is actually doing.”original · da:“Men det kan blive usundt, hvis vi lever på Novos nåde ... Hvis man ikke er opmærksom, kan én virksomhed altså forvrænge billedet af, hvordan dansk økonomi egentlig har det.”
https://nyheder.tv2.dk/business/2023-08-10-novo-nordisks-succes-risikerer-at-goere-dansk-oekonomi-usund-advarer-professor - [39]Novo Nordisk er dansk økonomis fede guldæg — Nordnet (Lars Christensen)Tier 2neutralHigh confidence
Danish economist Lars Christensen calculated that without the pharmaceutical sector, Denmark's real GDP would have shrunk 0.3% over a period it actually grew 1.7% — underscoring single-sector concentration risk.
“Denmark's real GDP rose 1.7 percent in that period. But if we remove the pharmaceutical industry's contribution, our economy would actually have shrunk by 0.3 percent.”original · da:“Danmarks real BNP steg med 1,7 procent i den periode. Men hvis vi fjerner medicinalindustriens bidrag, ville vores økonomi faktisk være gået tilbage med 0,3 procent.”
https://www.nordnet.dk/blog/novo-nordisk-er-dansk-oekonomis-fede-guldaeg/ - [40]Mærkeligt svar fra finansministeren om Novo Nordisks effekt på dansk økonomi — Økonomisk UgebrevTier 2criticalHigh confidence
Asked in late 2025 to quantify Novo's effect on GDP, Denmark's finance minister declined 'for confidentiality reasons'; the disclosure noted Novo Holdings paid DKK 15.29bn in corporate tax for 2023.
“Due to confidentiality considerations it is not possible to make an estimate of individual companies' contribution to GDP ... Novo Holdings A/S' corporate tax payments amounted to DKK 15,288,363,847.”original · da:“Som følge af diskretionshensyn er det ikke muligt at lave et estimat for enkeltvirksomheders bidrag til BNP ... Novo Holdings A/S' selskabsskattebetalinger udgjorde 15.288.363.847 kr.”
https://ugebrev.dk/finans/maerkeligt-svar-fra-finansministeren-om-novo-nordisks-effekt-paa-dansk-oekonomi/ - [41]Novo Nordisk i kæmpe sparerunde: Vil fyre tusindvis i Danmark — Fagbladet 3FTier 2neutralHigh confidence
Novo cut ~9,000 jobs (≈5,000 in Denmark — more than one in seven Danish positions) to save DKK 8bn, per Danish union coverage.
“the group eliminates 9,000 positions ... around 5,000 positions in Denmark ... more than every seventh position in Denmark is to be cut away.”original · da:“koncernen nedlægge 9000 stillinger ... omkring 5000 stillinger i Danmark ... mere end hver syvende stilling i Danmark skal skæres væk.”
https://fagbladet3f.dk/novo-nordisk-i-kaempe-sparerunde-vil-fyre-tusindvis-i-danmark/ The union Djøf called Novo's layoff process 'chaotic and opaque,' saying there were no clear messages about which departments would be cut; about 100 members sought legal help.
“There are no clear messages about the order of the departments being affected.”original · da:“Der er ikke klare meldinger på rækkefølgen af afdelinger, som berøres.”
https://www.djoefbladet.dk/artikler/2025/10/novo-fyringsrundeOutgoing CEO Lars Fruergaard Jørgensen acknowledged Novo was 'in a crisis of confidence' after repeated downgrades, reflected in the share price.
“I think we are in a crisis of confidence, because we have downgraded. We have disappointed several times in short succession, and that is reflected in the share price.”original · da:“Jeg tror, at vi er i en tillidskrise, fordi vi har nedjusteret. Vi har skuffet flere gange med kort interval, og det afspejler sig i aktiekursen.”
https://www.dr.dk/nyheder/penge/skal-der-fyres-det-kommer-der-jo-sikkert-til-siger-afgaaende-novo-topchef-i-sit-sidste- [44]Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S — GlobeNewswireTier 1neutralHigh confidence
At a Nov 14, 2025 extraordinary general meeting, former CEO Lars Rebien Sørensen was elected chair as the Foundation replaced most of the board, including outgoing chair Helge Lund.
“Lars Rebien Sørensen was elected as chair of the Board of Directors, and Cees de Jong was elected as vice chair.”
https://www.globenewswire.com/news-release/2025/11/14/3188377/0/en/Resolutions-from-the-Extraordinary-General-Meeting-of-Novo-Nordisk-A-S.html - [45]Novo Nordisk Fonden foreslår nye kandidater til bestyrelsen — Novo Nordisk Fonden (via Ritzau)Tier 1neutralHigh confidence
The Foundation framed Sørensen's chairmanship as temporary — two to three years — to support new management's turnaround and recruit a permanent chair.
“with the intention that he hold the post for a temporary period of two to three years.”original · da:“med intention om, at han varetager posten i en midlertidig periode på to-tre år.”
https://via.ritzau.dk/pressemeddelelse/14630782/novo-nordisk-fonden-foreslar-nye-kandidater-til-valg-til-bestyrelsen-i-novo-nordisk-as - [46]Lars Rebien har sat sig på magten i Novo Nordisk, siger analytiker — TV 2Tier 2criticalHigh confidence
Danish commentators called the board takeover a 'power demonstration': Børsen's editor-in-chief said he could not recall anything like it at the top of Danish business; a correspondent likened it to 'throwing a hand grenade into the boardroom.'
“That Lars Rebien Sørensen takes the position himself unleashes his total power in Novo Nordisk ... I cannot recall having seen anything similar at the top of Danish business life.”original · da:“At Lars Rebien Sørensen selv tager positionen, forløser hans totale magt i Novo Nordisk ... Jeg kan ikke huske at have set noget lignende i toppen af dansk erhvervsliv.”
https://nyheder.tv2.dk/business/2025-10-21-lars-rebien-har-sat-sig-paa-magten-i-novo-nordisk-siger-analytiker - [47]Ny Novo-formand har ikke flertal blandt almindelige aktionærer — DRTier 2criticalHigh confidence
Excluding the Foundation's ~77% voting bloc, only 38.7% of ordinary shareholders backed Sørensen as chair (61.3% against), and experts warned of risks from concentrating power in one person.
“Excluding the foundation's votes, Lars Rebien Sørensen got support from only 38.7 percent of the votes, while 61.3 percent turned thumbs down.”original · da:“Fratrukket fondens stemmer fik Lars Rebien Sørensen kun opbakning fra 38,7 procent af stemmerne, mens 61,3 procent vendte tommelfingeren nedad.”
https://www.dr.dk/nyheder/penge/ny-novo-formand-har-ikke-flertal-blandt-almindelige-aktionaerer - [72]Novo-chefen sliber sin sparekniv og ved allerede, hvem han går efter — TV 2Tier 2neutralMedium confidence
New CEO Mike Doustdar said the cuts target 'duplicates and dual functions,' concentrated in Denmark, redirecting savings into core diabetes and obesity, and signalled it would be a single decisive round.
“duplicates and dual functions ... It will not happen on my watch.”original · da:“dubletter og dobbeltfunktioner ... Det kommer ikke til at ske på min vagt.”
https://nyheder.tv2.dk/business/2025-09-10-novo-chefen-sliber-sin-sparekniv-og-ved-allerede-hvem-han-gaar-efter In October 2025 nearly the entire board departed early after the owner-Foundation and the board could not agree on the future composition, triggering the November EGM.
“The massive replacement happens after the main owner, Novo Nordisk Foundation, could not agree with the board on the future composition.”original · da:“Den kæmpemæssige udskiftning sker, efter at hovedejeren, Novo Nordisk Fonden, ikke har kunnet blive enige med bestyrelsen om den fremtidige sammensætning.”
https://www.dr.dk/nyheder/penge/novo-nordisk-udskifter-bestyrelsestoppen-foer-tidA DR correspondent argued Sørensen 'threw a hand grenade into the boardroom,' noting the unusual concentration of having the same person chair both Novo Nordisk and its controlling Foundation.
“Lars Rebien has thrown a hand grenade into the boardroom ... The same person sits at the head of the table in the boardroom for both Novo Nordisk and the owner-foundation.”original · da:“Lars Rebien har smidt en håndgranat ind i bestyrelseslokalet ... Den samme person sidder for bordenden i bestyrelseslokalet for både Novo Nordisk og for ejerfonden.”
https://www.dr.dk/nyheder/penge/lars-smed-lars-paa-porten-nu-goer-novos-nestor-noget-ingen-har-gjort-foer-ham- [77]Novo Nordisk Fonden bevilliger 5,5 mia. kr. til BII — Novo Nordisk Fonden (via Ritzau)Tier 1supportingHigh confidence
In January 2026 the Novo Nordisk Foundation allocated up to DKK 5.5bn (EUR 736m) to the BioInnovation Institute to boost life-science innovation in Denmark and Europe — an example of its philanthropic reinvestment.
“The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million) to BioInnovation Institute (BII).”original · da:“Novo Nordisk Fonden har afsat op til 5,5 mia. kr. (736 mio. EUR) til BioInnovation Institute (BII).”
https://via.ritzau.dk/pressemeddelelse/14749230/novo-nordisk-fonden-bevilliger-55-mia-kr-til-bii-til-at-lofte-innovation-i-danmark-og-europa?publisherId=13560118&lang=da
Peer Comparison & Benchmarking
- [48]Lilly hikes revenue forecasts on booming obesity drug sales — BioPharma DiveTier 2criticalHigh confidence
Eli Lilly reported FY2025 revenue of about $65bn (+45% YoY), far outpacing Novo's ~DKK 309bn (~$48bn), and is valued at roughly $0.95tn vs Novo's ~$186bn.
“Lilly raised its full-year revenue guidance to between $63 billion and $63.5 billion.”
https://www.biopharmadive.com/news/lilly-third-quarter-2025-earnings-zepbound-mounjaro-obesity-sales/804232/ Roche reported 2025 group sales of CHF 61.5bn (+7% CER), with pharmaceuticals at CHF 47.7bn (+9% CER) — a diversified large-cap peer growing more slowly than the GLP-1 leaders.
“Group sales ... CHF 61.5 billion ... 7% ... Pharmaceuticals Division ... CHF 47.7 billion ... 9%.”
https://www.roche.com/investors/updates/inv-update-2026-01-29AstraZeneca reported 2025 total revenue of roughly $58.7bn (up from $54.1bn in 2024), making it comparable in scale to Novo but with a different oncology-led mix.
“AstraZeneca's total revenue for 2025 was $58.739 billion.”
https://www.sec.gov/Archives/edgar/data/0000901832/000110465926019130/azn-20251231x20f.htmNovo's profitability remains elite by pharma standards — FY2025 operating profit of DKK 127.7bn on DKK 309bn of sales (~41% operating margin) — even after margin compression.
“Operating profit ... DKK 127,658 million.”
https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.htmlBy Q1 2026 Lilly's Mounjaro alone ($8.66bn, +125%) was approaching the size of Novo's entire quarterly adjusted sales (~DKK 70bn), illustrating how fast the gap widened.
“Mounjaro generated $8.66 billion in quarterly revenue for Q1 2026 ... a 125% year-over-year increase.”
https://247wallst.com/investing/2026/05/04/eli-lilly-captures-60-of-the-glp-1-market-as-mounjaro-revenue-soars-125/
Financials, the Stock & Growth
Novo grew FY2025 sales 10% at CER to DKK 309bn and net profit 1% to DKK 102.4bn — still highly profitable, but a sharp deceleration from the GLP-1 boom years.
“Net profit increased by 1% to DKK 102,434 million.”
https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.htmlNovo's market value fell to about $186bn by June 2026, from a 2024 peak that briefly made it Europe's most valuable listed company — a decline of well over half.
“Market cap ... $186.05 Billion USD ... as of June 2026.”
https://companiesmarketcap.com/novo-nordisk/marketcap/Novo shares fell ~48% in 2025 and hit a four-year low below $44 in late November 2025, leaving the company worth roughly one-fifth of Eli Lilly.
“Novo Nordisk shares have fallen 48% in 2025 and hit a four-year low ... falling below $44 a share ... market cap is listed at $142 billion, approximately one-fifth of Eli Lilly's.”
https://www.fool.com/investing/2025/11/29/why-novo-nordisk-shares-just-hit-a-four-year-low/- [56]Er Novo Nordisk i krise? Nej, siger topchef efter blodbad på børsen — DRTier 2criticalHigh confidence
On its February 2026 results, Danish coverage reported the share fell 18% at the Copenhagen open and was down over 70% from its June-2024 peak, even as the CEO denied the company was in crisis.
“The share fell 18 percent at the opening of the Danish stock exchange today ... if you look back to June 2024, when the share peaked, there has been a fall of over 70 percent.”original · da:“Aktien faldt med 18 procent ved åbningen af den danske fondsbørs i dag ... hvis man ser tilbage til juni 2024, hvor aktien toppede, så er der sket et fald på over 70 procent.”
https://www.dr.dk/nyheder/penge/er-novo-nordisk-i-krise-nej-siger-topchef-efter-historisk-melding-og-blodbad-paa-boersen - [57]Novo Nordisk Q1 2026 slides: Wegovy pill drives outlook raise despite sales decline — Investing.comTier 2neutralHigh confidence
For 2026 Novo guides adjusted sales and operating profit to fall 4%–12% at CER (improved from −5% to −13%) after a stronger-than-expected Wegovy-pill launch; Q1 2026 adjusted sales were −4% CER.
“adjusted sales growth of -4% to -12% at constant exchange rates ... Adjusted sales of DKK 70.1 billion declined 4% at constant exchange rates.”
https://www.investing.com/news/company-news/novo-nordisk-q1-2026-slides-wegovy-pill-drives-outlook-raise-despite-sales-decline-93CH-4681178 Novo proposed a dividend of DKK 11.70 per share for 2025, continuing shareholder returns even as growth slowed.
“Novo Nordisk paid a dividend of 11.70 per share for 2025.”
https://en.wikipedia.org/wiki/Novo_Nordisk- [75]Novo Nordisk varsler for første gang i 25 år et fald i omsætningen — DRTier 2criticalHigh confidence
Danish coverage stressed the symbolic shift: with the 2025 results Novo warned of a fall in revenue for the first time in about 25 years.
“Novo Nordisk warns, for the first time in 25 years, of a fall in revenue.”original · da:“Novo Nordisk varsler for første gang i 25 år et fald i omsætningen.”
https://www.dr.dk/nyheder/penge/novo-praesenterer-aarsregnskab Danish coverage confirmed FY2025 sales of just over DKK 309bn with ~6% growth in kroner and net profit of DKK 102.4bn.
“Novo Nordisk had revenue of just over 309 billion kroner in 2025 and growth of six percent.”original · da:“Novo Nordisk havde en omsætning på lidt over 309 milliarder kroner i 2025 og en vækst på seks procent.”
https://www.tv2east.dk/kalundborg/novo-nordisk-tjente-over-300-milliarder-kroner-sidste-ar-4d4f8- [81]Novo Nordisks regnskab: 'ikke de store tegn på fremgang' — Danske BankTier 2criticalHigh confidence
Danske Bank's equity-research chief Carsten Lønborg Madsen summed up the results bluntly: 'there really aren't great signs of progress,' citing competition, weak Wegovy growth and US headwinds.
“To be completely honest, there really aren't great signs of progress.”original · da:“Der er helt ærligt ikke de store tegn på fremgang.”
https://danskebank.dk/privat/investering/artikler/novo-nordisk-regnskab
Risks & Challenges
- [59]Novo Nordisk is losing Canadian patent protection after not paying a small fee — FortuneTier 2criticalHigh confidence
Semaglutide faces a global patent cliff: protection lapsed in Canada in early 2026 (after a missed maintenance fee) and expires in markets such as India and China around 2026, with generics already launching; US protection runs to roughly 2032.
“Novo Nordisk ... is losing Canadian patent protection on ... semaglutide after not paying a small fee.”
https://fortune.com/2025/06/17/novo-nordisk-ozempic-wegovy-semaglutide-canada-patent-protection-fee/ - [60]Trump announces deals with Lilly, Novo to slash weight-loss drug prices — CNBCTier 2criticalHigh confidence
In November 2025 the Trump administration announced deals with Novo and Lilly to cut US obesity-drug prices: ~$245 in Medicare/Medicaid, ~$350 (trending to $245) cash via TrumpRx, and ~$149–150 starting doses for the pills.
“The prices of Ozempic and Wegovy will fall ... to $350 when purchased through TrumpRx ... trend down to $245 ... obesity pills ... $149 per month.”
https://www.cnbc.com/2025/11/06/trump-eli-lilly-novo-nordisk-deal-obesity-drug-prices.html - [61]EMA finds no link between GLP-1 receptor agonists and suicidal thoughts — The Pharmaceutical JournalTier 2supportingHigh confidence
Regulators have scrutinized GLP-1 safety; after a 2023–2024 review the EMA's PRAC concluded in April 2024 there was no evidence linking GLP-1 medicines to suicidal or self-injurious thoughts, and recommended no label change.
“no update to the product information is warranted ... no evidence that GLP-1 RAs are linked to suicidal and self-injurious thoughts.”
https://pharmaceutical-journal.com/article/news/ema-finds-no-link-between-glp-1-receptor-agonists-and-suicidal-thoughts Novo's revenue is concentrated in a single molecule: semaglutide (Ozempic + Rybelsus + Wegovy) was roughly two-thirds of FY2025 sales, so any clinical, patent or pricing shock to it is magnified.
“Ozempic ... DKK 127,089 million ... Rybelsus ... DKK 22,093 million.”
https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.htmlDanish coverage shows pricing tension at home: an Ozempic pen cost DKK 975 in Denmark versus DKK 549 in Norway, and Danish regions' bill for Novo medicines pressured budgets and waiting lists.
“The same Ozempic pen ... currently costs 975 kroner in Denmark ... and only 549 Danish kroner in Norway.”original · da:“Den samme Ozempic-pen ... koster aktuelt 975 kroner i Danmark ... og blot 549 danske kroner i Norge.”
https://www.dr.dk/nyheder/indland/milliardudgifter-til-novomedicin-presser-regionerne-danmark-har-betalt-naesten- [64]Dokumenter afslører: Novo Nordisk krævede tilskud til populær medicin — DRTier 2criticalHigh confidence
Documents reported by DR showed Novo would file lower Danish prices only after the Medicines Agency signalled it would keep a general subsidy; a Cochrane professor called the price cut 'a pure confession' of pressure.
“Novo Nordisk will file the new prices ... immediately after the Medicines Agency has indicated ... it will maintain a general conditional subsidy ... The price reduction is a pure confession.”original · da:“Novo Nordisk vil anmelde de nye priser i Taksten umiddelbart efter, at Lægemiddelstyrelsen overfor Novo Nordisk har indikeret at ville opretholde et generelt klausuleret tilskud ... Prisnedsætningen er en ren tilståelsessag.”
https://www.dr.dk/nyheder/indland/dokumenter-afsloerer-novo-nordisk-lavede-aftale-med-styrelse-om-tilskud-til-populaer - [65]Heine Andersen: Novo-milliarder skaber større problemer — Altinget ForskningTier 2criticalHigh confidence
Critics argue the Foundation's dominance carries societal risk: KU professor emeritus Heine Andersen warned that foundation billions skew research priorities and 'threaten free research' at universities.
“the universities' ability to prioritise independently between fields and projects will disappear ... Both threaten free research.”original · da:“universiteternes muligheder for en selvstændig prioritering mellem områder og projekter vil forsvinde ... Begge truer den frie forskning.”
https://www.altinget.dk/forskning/artikel/professor-novo-milliarder-skaber-stoerre-problemer - [66]Penge fra Novo Nordisk er overalt i den danske sundhedssektor — InformationTier 2criticalMedium confidence
Some Danish health-sector voices call the Foundation's pervasive funding 'a Trojan horse,' warning that experts dependent on Novo money are not fully independent.
“a Trojan horse in the Danish health service ... Gradually Novo is everywhere. We can't do without them.”original · da:“en trojansk hest i det danske sundhedsvæsen ... Efterhånden er Novo overalt. Vi kan ikke undvære dem.”
https://www.information.dk/moti/2023/01/penge-novo-nordisk-overalt-danske-sundhedssektor On the environment, the Danish Society for Nature Conservation accused Novo of 'self-interest' for seeking to discharge facility wastewater into a protected wetland with Annex-4 species rather than build its own basin.
“Instead of establishing a rainwater basin on its own property, Novo Nordisk will discharge more wastewater into a protected wetland with specially protected Annex-4 species.”original · da:“I stedet for at etablere regnvandsbassin på egen matrikel vil Novo Nordisk lukke mere spildevand ud til en fredet mose med særligt beskyttede bilag 4-arter.”
https://pro.ing.dk/watertech/artikel/novo-nordisk-beskyldes-miljoesjusk-vil-udlede-spildevand-til-mose-med-sjaeldne-arter
Forward View
- [68]Is Novo Nordisk Stock a Buy After its Share Price Collapse? — MorningstarTier 2supportingMedium confidence
Bulls argue the sell-off has gone too far: Morningstar viewed the stock as undervalued after its collapse, pointing to a still-dominant franchise and deep pipeline.
“Is Novo Nordisk Stock a Buy After its Share Price Collapse?”
https://www.morningstar.com/stocks/is-novo-nordisk-stock-buy-after-its-share-price-collapse Bears counter that even after the fall the shares are not obviously cheap given the 2026 decline, pricing reset and intensifying competition — some analysts have downgraded.
“Novo Nordisk's Is Not Cheap.”
https://seekingalpha.com/article/4852441-novo-nordisks-is-not-cheap-rating-downgrade- [70]Eli Lilly set to leapfrog Novo Nordisk in weight-loss drug race — S&P GlobalTier 2criticalMedium confidence
S&P Global assessed in 2025 that Eli Lilly was set to leapfrog Novo Nordisk in the weight-loss-drug race — a structural shift, not a one-quarter blip.
“Eli Lilly ... is expected to overtake Novo Nordisk ... in the fast-expanding GLP-1 drug market.”
https://www.spglobal.com/market-intelligence/en/news-insights/research/2025/08/eli-lilly-set-to-leapfrog-novo-nordisk-in-weight-loss-drug-race - [71]Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger Q1 — Manufacturing ChemistTier 2supportingMedium confidence
The forward case hinges on execution of the oral franchise and next-gen pipeline: the Wegovy pill drove a 2026 guidance raise, while amycretin and CagriSema are the swing factors for re-acceleration.
“the oral pill was driving a strong start to 2026 ... led the company to raise its 2026 guidance.”
https://manufacturingchemist.com/novo-nordisk-2026-guidance-wegovy-pill-q1-earnings - [83]Novo Nordisk hæver sine forventninger til regnskabsåret 2026 — Unge InvestorerTier 3supportingMedium confidence
On the Q1 2026 report Novo raised its 2026 outlook from −5/−13% to −4/−12% on higher GLP-1 sales, led by the Wegovy pill — a modest positive read on the turnaround.
“Due to higher sales of GLP-1 products, Novo Nordisk has, in connection with today's quarterly report, chosen to raise this to negative growth of 4–12%.”original · da:“Som følge af et højere salg af GLP-1-produkter, har Novo Nordisk i forbindelse med dagens kvartalsregnskab valgt at opjustere dette til en negativ vækst på 4-12%.”
https://www.ungeinvestorer.dk/novo-nordisk-haever-sine-forventninger-til-regnskabsaaret-2026/